ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24) von Pagel, J., Reddy, N., Jagadeesh, D., Stathis, A., Asch, A. S., Salman, H., Kenkre, V. P., Soumerai, J. D., Llorin‐Sangalang, J., Gorbatchevsky, I., Li, J., Zelenetz, A. D.

Volltext

THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) von Zelenetz, A.D., Jagadeesh, D., Kenkre, V.P., Reddy, N.M., Stathis, A., Salman, H.S., Asch, A.S., Soumerai, J., Jhangiani, H.S., Iasonos, A., Patel, K., Carter, J., LLorin‐Sangalang, J., Pagel, J.M.

Volltext

A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE... von Zelenetz, A., Zinzani, P., Buske, C., Ribrag, V., Cunningham, D., Jurczak, W., Abrisqueta, P., Agajanian, R., Chaudhry, A., Kayyal, T., Wood, J., Llorin‐Sangalang, J., Brown, J.

Volltext

Abstract OT3-06-01: SHERBOC: A double-blind, placebo-controlled, phase 2 trial of seribantumab (MM-121) plus fulvestrant in postmenopausal women with hormone receptor-positive, her... von Kaufman, PA, Pipas, M, Finn, GJ, Mathews, SE, Zhang, H, Richards, J, Kudla, AJ, Bloom, T, Zalutskaya, AA, Llorin-Sangalang, J, Pinto, AC, Ettl, J

Volltext